Comparative Pharmacology
Head-to-head clinical analysis: TRICOR MICRONIZED versus TRIGLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRICOR MICRONIZED versus TRIGLIDE.
TRICOR (MICRONIZED) vs TRIGLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricor (micronized fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
Initial 48 mg (1 tablet) orally once daily with meals. May increase to 96 mg (2 tablets) once daily with meals. Maximum dose 96 mg/day.
Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 15-25 hours) in patients with normal renal function. Half-life is prolonged in renal impairment, requiring dose adjustment when eGFR < 30 mL/min/1.73 m².
22-35 hours; prolonged in renal impairment (up to 50 hours).
Primarily renal excretion of glucuronide conjugate, accounting for approximately 60-70% of elimination; fecal excretion accounts for about 25%. Minimal unchanged drug in urine.
Primarily renal (70% as unchanged drug), 20% fecal, <10% biliary.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic